Vanda Pharmaceuticals Provides an Update to HETLIOZ® ANDA Litigation Appeal: Federal Circuit grants motion to temporarily enjoin generic launch
WASHINGTON,Dec. 16, 2022/PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq:VNDA今天提供了一个更新它的吸引力的再保险cent HETLIOZ®ANDA litigation ruling.
OnDecember 14, 2022, Vanda appealed theDecember 13thdecision ofthe United StatesDistrict Court for the District ofDelawarein the HETLIOZ®ANDA litigation tothe United StatesCourt of Appeals for the Federal Circuit and requested an injunction prohibiting market entry by Teva PharmaceuticalsUSA, Inc. (Teva) and Apotex Inc. (Apotex) while the appeal is pending. Today, the Court granted a temporary injunction to prohibit market entry by Teva and Apotex until at leastJanuary 6, 2023while the Court considers Vanda's pending motion for an injunction that would extend until the Court decides the appeal.
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visitwww.vandapharma.comand follow us on Twitter @vandapharma.
For full U.S. Prescribing Information for HETLIOZ®and HETLIOZ LQ®, including indication and Important Safety Information, visitwww.hetlioz.com.
Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
[email protected]
Elizabeth Van Every
公司的负责人rporate Affairs
Vanda Pharmaceuticals Inc.
202-734-3400
[email protected]
SOURCE Vanda Pharmaceuticals Inc.
Share this article